Treatment with Glimepiride, but not Mitiglinide and Short-Acting Insulin, Resists Body Weight and Abdominal Fat Reduction Under Dietary Energy Restriction

Nakano, Takamitsu; Inoue, Ituro; Satoh, Kanako; Yamazaki, Mochihito; Awata, Takuya; Kurihara, Susumu; Goto, Seiichi; Shinoda, Yasutoshi; Komoda, Tsugikazu; Katayama, Shigehiro

doi:10.5551/jat.e587

Cited by 4 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Especially for obese patients, the combination of calorie restriction and mitiglinide administration lowered the visceral fat area and body weight, whereas glimepiride with restricted diet did not significantly reduce visceral fat area or body weight [105]. These findings suggest that combined use of mitiglinide with calorie restriction is warranted in patients with obesity and/or metabolic syndrome, and that short-acting oral hyperglycemic agents and exogenous short-acting insulin are useful for those attempting to undergo lifestyle modification [105].…”

Section: How Can Mitiglinide Be Used To Prevent Cardiovascular Disease?mentioning

confidence: 99%

“…These findings suggest that combined use of mitiglinide with calorie restriction is warranted in patients with obesity and/or metabolic syndrome, and that short-acting oral hyperglycemic agents and exogenous short-acting insulin are useful for those attempting to undergo lifestyle modification [105]. …”

Section: How Can Mitiglinide Be Used To Prevent Cardiovascular Disease?mentioning

confidence: 99%

See 1 more Smart Citation

Postprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinide

Kitasato

Tojo

Hatakeyama

et al. 2012

Cardiovasc Diabetol

View full text Add to dashboard Cite

The risk of cardiovascular complication in a diabetes patient is similar to that in a nondiabetic patient with a history of myocardial infarction. Although intensive control of glycemia achieved by conventional antidiabetic agents decreases microvascular complications such as retinopathy and nephropathy, no marked effect has been reported on macrovascular complications or all-cause mortality. Evidence from VADT, ACCORD, and ADVANCE would suggest that glycemic control has little effect on macrovascular outcomes. Moreover, in the case of ACCORD, intensive glycemic control may be associated with an increased risk of mortality. There is sufficient evidence that suggests that postprandial hyperglycemia may be an independent risk factor for cardiovascular disease in diabetes patients. However, there are no prospective clinical trials supporting the recommendation that lowering postprandial blood glucose leads to lower risk of cardiovascular outcomes. Mitiglinide is a short-acting insulinotropic agent used in type 2 diabetes treatment. It has a rapid stimulatory effect on insulin secretion and reduces postprandial plasma glucose level in patients with type 2 diabetes. Because of its short action time, it is unlikely to exert adverse effects related to hypoglycemia early in the morning and between meals. Mitiglinide reduces excess oxidative stress and inflammation, plays a cardioprotective role, and improves postprandial metabolic disorders. Moreover, mitiglinide add-on therapy with pioglitazone favorably affects the vascular endothelial function in type 2 diabetes patients. These data suggest that mitiglinide plays a potentially beneficial role in the improvement of postprandial hyperglycemia in type 2 diabetes patients and can be used to prevent cardiovascular diseases. Although the results of long-term, randomized, placebo-controlled trials for determining the cardiovascular effects of mitiglinide on clinical outcomes are awaited, this review is aimed at summarizing substantial insights into this topic.

show abstract

Section: How Can Mitiglinide Be Used To Prevent Cardiovascular Disease?mentioning

confidence: 99%

Section: How Can Mitiglinide Be Used To Prevent Cardiovascular Disease?mentioning

confidence: 99%

Postprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinide

Kitasato

Tojo

Hatakeyama

et al. 2012

Cardiovasc Diabetol

View full text Add to dashboard Cite

show abstract

Mitiglinide: A Novel Agent for the Treatment of Type 2 Diabetes Mellitus

Phillippe

Wargo

2010

Ann Pharmacother

View full text Add to dashboard Cite

show abstract

Mitiglinide for type 2 diabetes treatment

Phillippe

Wargo

2013

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Meglitinides are limited by their cost, frequency of administration, and minimal available data assessing clinical impact; however, mitiglinide shows selective action on the pancreatic β-cells, has greater affinity for β-cells, and limited metabolism when compared to other meglitinides. These properties may allow more utility in patients with chronic kidney disease or at high risk of hypoglycemia. The primary role in therapy for mitiglinide is the treatment of elevated postprandial glucose in patients with T2DM.

show abstract

Treatment with Glimepiride, but not Mitiglinide and Short-Acting Insulin, Resists Body Weight and Abdominal Fat Reduction Under Dietary Energy Restriction

Cited by 4 publications

References 10 publications

Postprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinide

Postprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinide

Mitiglinide: A Novel Agent for the Treatment of Type 2 Diabetes Mellitus

Mitiglinide for type 2 diabetes treatment

Contact Info

Product

Resources

About